Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
Hanako Hasegawa(Keio University), Kenzo Soejima(Keio University), Tetsuo Tani(Keio University), Keigo Kobayashi(Keio University), Keita Masuzawa(Kitasato Institute Hospital), Shinnosuke Ikemura(Keio University), Hideki Terai(Kitasato Institute Hospital), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Tadashi Manabe(Keio University), Toshiyuki Hirano(Sapporo Kosei General Hospital), Shigenari Nukaga(Tokyo Medical Center)
Cited by 50
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101